Cargando…

Consequences of excessive glucosylsphingosine in glucocerebrosidase-deficient zebrafish.

In Gaucher disease (GD), the deficiency of glucocerebrosidase causes lysosomal accumulation of glucosylceramide (GlcCer), which is partly converted by acid ceramidase to glucosylsphingosine (GlcSph) in the lysosome. Chronically elevated blood and tissue GlcSph is thought to contribute to symptoms in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lelieveld, Lindsey T., Gerhardt, Sophie, Maas, Saskia, Zwiers, Kimberley C., de Wit, Claire, Beijk, Ernst H., Ferraz, Maria J., Artola, Marta, Meijer, Annemarie H., Tudorache, Christian, Salvatori, Daniela, Boot, Rolf G., Aerts, Johannes M.F.G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Biochemistry and Molecular Biology 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058576/ https://www.ncbi.nlm.nih.gov/pubmed/35315333 http://dx.doi.org/10.1016/j.jlr.2022.100199

Ejemplares similares

Xylose‐Configured Cyclophellitols as Selective Inhibitors for Glucocerebrosidase
por: Su, Qin, et al.
Publicado: (2021)

Human glucocerebrosidase mediates formation of xylosyl-cholesterol by β-xylosidase and transxylosidase reactions
por: Boer, Daphne E., et al.
Publicado: (2021)

Glucocerebrosidase: Functions in and Beyond the Lysosome
por: Boer, Daphne E.C., et al.
Publicado: (2020)

Functionalized Cyclophellitols Are Selective Glucocerebrosidase Inhibitors and Induce a Bona Fide Neuropathic Gaucher Model in Zebrafish
por: Artola, Marta, et al.
Publicado: (2019)

Stabilization of Glucocerebrosidase by Active Site Occupancy
por: Ben Bdira, Fredj, et al.
Publicado: (2017)

Fabry Disease: Molecular Basis, Pathophysiology, Diagnostics and Potential Therapeutic Directions
por: Kok, Ken, et al.
Publicado: (2021)

In vivo inactivation of glycosidases by conduritol B epoxide and cyclophellitol as revealed by activity‐based protein profiling
por: Kuo, Chi‐Lin, et al.
Publicado: (2019)

Design, Synthesis and Structural Analysis of Glucocerebrosidase Imaging Agents
por: Rowland, Rhianna J., et al.
Publicado: (2021)

Investigations on therapeutic glucocerebrosidases through paired detection with fluorescent activity-based probes
por: Kallemeijn, Wouter W., et al.
Publicado: (2017)

HEPES‐buffering of bicarbonate‐containing culture medium perturbs lysosomal glucocerebrosidase activity
por: van der Lienden, Martijn J. C., et al.
Publicado: (2022)

Lyso-glycosphingolipids: presence and consequences
por: van Eijk, Marco, et al.
Publicado: (2020)

Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits
por: Sun, Ying, et al.
Publicado: (2010)

Optic Nerve Lipidomics Reveal Impaired Glucosylsphingosine Lipids Pathway in Glaucoma
por: Chauhan, Muhammad Zain, et al.
Publicado: (2019)

Plasma Glucosylsphingosine in GBA1 Mutation Carriers with and without Parkinson's Disease
por: Surface, Matthew, et al.
Publicado: (2021)

Glycosphingolipids and Infection. Potential New Therapeutic Avenues
por: Aerts, Johannes M. F. G., et al.
Publicado: (2019)

Glucocerebrosidase mutations and Parkinson disease
por: Vieira, Sophia R. L., et al.
Publicado: (2022)

Galactosyl- and glucosylsphingosine induce lysosomal membrane permeabilization and cell death in cancer cells
por: Stahl-Meyer, Kamilla, et al.
Publicado: (2022)

Contribution of Glucosylsphingosine (Lyso-Gb1) to Treatment Decisions in Patients with Gaucher Disease
por: Dinur, Tama, et al.
Publicado: (2023)

Mitochondrial dysfunction associated with glucocerebrosidase deficiency
por: Gegg, Matthew E., et al.
Publicado: (2016)

Neurological effects of glucocerebrosidase gene mutations
por: Mullin, S., et al.
Publicado: (2018)

Glucosylsphingosine (Lyso-Gb(1)): An Informative Biomarker in the Clinical Monitoring of Patients with Gaucher Disease
por: Gayed, Matthew M., et al.
Publicado: (2022)

Parkinsonisms and Glucocerebrosidase Deficiency: A Comprehensive Review for Molecular and Cellular Mechanism of Glucocerebrosidase Deficiency
por: Gatto, Emilia M., et al.
Publicado: (2019)

Novel pathogenic mutations in the glucocerebrosidase locus
por: Duran, Raquel, et al.
Publicado: (2012)

Parkinsonism Associated with Glucocerebrosidase Mutation
por: Sunwoo, Mun-Kyung, et al.
Publicado: (2011)

Glucocerebrosidase mutations in primary parkinsonism
por: Asselta, Rosanna, et al.
Publicado: (2014)

The heat shock protein amplifier arimoclomol improves refolding, maturation and lysosomal activity of glucocerebrosidase
por: Fog, Cathrine K., et al.
Publicado: (2018)

The relationship between glucocerebrosidase mutations and Parkinson disease
por: Migdalska‐Richards, Anna, et al.
Publicado: (2016)

Glucosylsphingosine Causes Hematological and Visceral Changes in Mice—Evidence for a Pathophysiological Role in Gaucher Disease
por: Lukas, Jan, et al.
Publicado: (2017)

Glucosylsphingosine (lyso-Gb1) as a Biomarker for Monitoring Treated and Untreated Children with Gaucher Disease
por: Hurvitz, Noa, et al.
Publicado: (2019)

The role of glucosylsphingosine as an early indicator of disease progression in early symptomatic type 1 Gaucher disease
por: Stiles, Ashlee R., et al.
Publicado: (2021)

Glucosylsphingosine (Lyso-Gb1) as a reliable biomarker in Gaucher disease: a narrative review
por: Giuffrida, Gaetano, et al.
Publicado: (2023)

A new multiplex analysis of glucosylsphingosine and globotriaosylsphingosine in dried blood spots by tandem mass spectrometry
por: Van Baelen, Amber, et al.
Publicado: (2023)

Visualization of Active Glucocerebrosidase in Rodent Brain with High Spatial Resolution following In Situ Labeling with Fluorescent Activity Based Probes
por: Herrera Moro Chao, Daniela, et al.
Publicado: (2015)

Progranulin deficiency leads to reduced glucocerebrosidase activity
por: Zhou, Xiaolai, et al.
Publicado: (2019)

Glycoprotein Non-Metastatic Protein B: An Emerging Biomarker for Lysosomal Dysfunction in Macrophages
por: van der Lienden, Martijn J.C., et al.
Publicado: (2018)

Value of Glucosylsphingosine (Lyso-Gb1) as a Biomarker in Gaucher Disease: A Systematic Literature Review
por: Revel-Vilk, Shoshana, et al.
Publicado: (2020)

Glucocerebrosidase and its relevance to Parkinson disease
por: Do, Jenny, et al.
Publicado: (2019)

Localization of active endogenous and exogenous β‐glucocerebrosidase by correlative light‐electron microscopy in human fibroblasts
por: van Meel, Eline, et al.
Publicado: (2019)

Ambroxol effects in glucocerebrosidase and α‐synuclein transgenic mice
por: Migdalska‐Richards, Anna, et al.
Publicado: (2016)

Effect of Ambroxol chaperone therapy on Glucosylsphingosine (Lyso-Gb1) levels in two Canadian patients with type 3 Gaucher disease
por: Charkhand, Behshad, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_saih70agfdim8natveago5god1